Caplan participated in the forum's panel entitled "Cell and gene therapy: The financing surge."
Investor deep dive
Orgenesis leads the charge at an exciting time for cell therapy
Orgenesis CEO says investors realizing building out infrastructure in biotechs is important
Quick facts: Orgenesis
Market Cap: $68.76 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE